FIT 101
Alternative Names: FIT-101Latest Information Update: 28 Dec 2022
At a glance
- Originator FIT Biotech
- Class Antibodies; Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in Finland (Parenteral)
- 02 May 2019 ValiRx acquires global granted patents and intellectual property assets from FIT Biotech
- 28 Nov 2018 FIT 101 is available for licensing as of 28 Nov 2018. https://www.fitbiotech.com/about/company